重组人2型肿瘤坏死因子受体-抗体融合蛋白治疗寻常型银屑病的临床效果

Clinical Effect of Recombinant Human Tumor Necrosis Factor Receptor Type 2-antibody Fusion Protein in the Treatment of Psoriasis Vulgaris

目的 调查寻常型银屑病行重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)治疗的效果。方法选取2020年10月—2021年10月解放军第九七〇医院收治的92例寻常型银屑病患者,以自主抽签法分为参考组和观察组,每组46例;前者行阿维A治疗,后者行注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗。统计两组炎症指标,观察皮损恢复情况、治疗效果,记录不良反应。结果 治疗后,两组TNF-α、IL-17A水平均降低,且观察组比参考组低,差异有统计学意义(P<0.05)。治疗前,两组PASI评分、皮损面积对比,差异无统计学意义(P>0.05)。治疗后,两组PASI评分皮损面积均降低,且观察组比参考组低,差异有统计学意义(P<0.05)。治疗后,观察组治疗有效率97.83%比参考组82.61%高,差异有统计学意义(χ^(2)=4.434,P=0.035)。治疗后,观察组不良反应发生率6.52%比参考组23.91%低,差异有统计学意义(χ^(2)=5.394,P=0.020)。结论 益赛普有效性高,能减轻炎症病变,改善寻常型银屑病的相关症状,且不良反应少。

Objective To investigate the effect of recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein(Etanercept)in the treatment of psoriasis vulgaris.Methods From October 2020 to October 2021, 92 patients with psoriasis vulgaris admitted to the 970 Hospital of the People’s Liberation Army. They were divided into a reference group and an observation group by automatic drawing, with 46 cases in each group. The former was treated with acitretin, and the latter was treated with recombinant human type 2 tumor necrosis factor receptor antibody fusion protein for injection. The inflammatory indexes of the two groups were counted, the recovery of the skin lesions and the treatment effect were observed, and the adverse reactions were recorded.Results After treatment, the levels of TNF-α and IL-17A in the two groups were decreased, and the observation group was lower than the reference group,and the difference was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in PASI score and skin lesion area between the two groups(P>0.05). After treatment, the PASI scores and ckin fesionarea of the two groups were decreased, and the observation group was lower than the reference group, and the difference was statistically significant(P<0.05). After treatment, the effective rate of treatment in the observation group97.83% was higher than that in the reference group 82.61%, and the difference was statistically significant(χ^(2)=4.434,P=0.035). After treatment, the incidence of adverse reactions in the observation group 6.52% was lower than that in the reference group 23.91%, and the difference was statistically significant(χ^(2)=5.394, P=0.020).Conclusion Etanercept is highly effective, can reduce inflammatory lesions, improve the related symptoms of psoriasis vulgaris, and has few adverse reactions.